Loading...
01/10 16:33
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary highlights strong financial performance, with significant revenue and net income growth. Product development is promising, with market expansion for AGAMREE and strategic initiatives for FIRDAPSE. The Q&A reassures continued growth and strategic initiatives, though some uncertainty remains in R&D and SG&A. The market cap suggests a moderate reaction. Overall, the company's robust financial metrics, market strategy, and optimistic guidance outweigh minor uncertainties, indicating a positive stock price movement.
Total Revenue (Q2 2025) $146.6 million, an increase of 19.4% year-over-year. This growth reflects strong execution and sustained demand for the company's portfolio.
Total Revenue (First Half 2025) $288 million, a 30.2% increase year-over-year. This growth is attributed to strong execution and sustained demand.
Cash Position (End of Q2 2025) $652.8 million, reinforcing the company's ability to invest strategically for long-term growth.
FIRDAPSE Net Product Revenue (Q2 2025) $84.8 million, a growth of $7.5 million compared to Q2 2024. The year-over-year growth was impacted by the timing of the Change Healthcare cybersecurity breach in 2024, which shifted volume from Q1 2024 to Q2 2024.
FIRDAPSE Net Product Revenue (First Half 2025) $168.6 million, a 16.9% increase over the first half of 2024. This reflects the franchise's continued strength and return to expected sales cadence.
AGAMREE Net Product Revenue (Q2 2025) $27.4 million, a 213% increase year-over-year from Q2 2024. This growth is driven by steady conversion from other treatments, a strong 90% patient retention rate, and growing adoption across Duchenne's Centers of Excellence.
AGAMREE Net Product Revenue (First Half 2025) $49.4 million, up 398% from the prior year. This growth is attributed to transitions from branded and generic therapies, strong patient retention, and increasing prescriber engagement.
FYCOMPA Net Product Revenue (Q2 2025) $34.3 million, reflecting a year-over-year decrease of 6%. The decline is due to the impact of generic competition.
FYCOMPA Net Product Revenue (First Half 2025) $70 million, up 4.5% from the same period last year. This reflects solid performance despite the anticipated impact of generic competition.
Net Income Before Income Taxes (Q2 2025) $69.3 million, a 24.2% increase year-over-year compared to $55.8 million in Q2 2024. This growth is driven by strong financial performance and disciplined execution.
GAAP Net Income (Q2 2025) $52.1 million or $0.41 per diluted share, a 27.7% increase year-over-year compared to $40.8 million or $0.33 per diluted share in Q2 2024.
Non-GAAP Net Income (Q2 2025) $86.4 million or $0.68 per diluted share, compared to $69.6 million or $0.56 per diluted share in Q2 2024. This excludes amortization of intangible assets, stock-based compensation, income tax provision, and depreciation.
Cost of Sales Expense (Q2 2025) $20.6 million, compared to $15.4 million in Q2 2024. The increase is primarily due to royalties, including those for AGAMREE.
Research and Development Expenses (Q2 2025) $4.4 million, up 46% from $3.0 million in Q2 2024. This increase is mainly due to costs supporting ongoing AGAMREE studies.
Selling, General and Administrative Expenses (Q2 2025) $45.9 million, compared to $40.7 million in Q2 2024. The increase is driven by personnel costs, including the implementation of dedicated sales forces for FIRDAPSE and AGAMREE.
FIRDAPSE: Generated $84.8 million in Q2 2025, a $7.5 million increase from Q2 2024. Year-to-date revenue reached $168.6 million, a 16.9% increase over the first half of 2024. Focused on expanding reach in cancer-associated LEMS patients, with updated NCCN guidelines supporting growth.
AGAMREE: Achieved $27.4 million in Q2 2025, a 213% year-over-year increase. First half revenue reached $49.4 million, up 398% from 2024. Strong adoption across Duchenne's Centers of Excellence and high patient retention rate of 90%. Full-year revenue guidance reaffirmed at $100-$110 million.
FYCOMPA: Generated $34.3 million in Q2 2025, a 6% year-over-year decrease. First half revenue reached $70 million, up 4.5% from 2024. Facing generic competition but full-year revenue guidance remains at $90-$95 million.
Expansion in LEMS oncology segment: Focused on expanding FIRDAPSE's reach in cancer-associated LEMS patients, supported by updated NCCN guidelines and strategic partnerships with oncology practices.
Duchenne Muscular Dystrophy market: AGAMREE adoption expanding across key centers, with 93% of top DMD centers of excellence engaged and high reimbursement success rate of 85%.
Revenue growth: Total revenue for Q2 2025 reached $146.6 million, a 19.4% year-over-year increase. First half revenue grew 30.2% to $288 million.
Cash position: Ended Q2 2025 with $652.8 million in cash, up from $517.6 million at the end of 2024, driven by strong cash flow generation.
R&D investment: R&D expenses increased by 46% year-over-year to $4.4 million in Q2 2025, primarily supporting AGAMREE studies.
Leadership changes: Dr. Will Andrews appointed as Chief Medical Officer, bringing expertise in rare diseases. Dr. Dan Curran joined the Board of Directors, enhancing strategic growth capabilities.
Business development: Actively evaluating opportunities aligned with long-term growth strategy. Awaiting trial date for FIRDAPSE patent litigation, with Markman hearing scheduled for October 2025.
Generic competition for FYCOMPA: The company anticipates revenue erosion for FYCOMPA due to the impact of generic competition following the loss of exclusivity in May 2025. This is expected to affect performance in the second half of the year and beyond.
Patent litigation for FIRDAPSE: Ongoing patent litigation for FIRDAPSE with first filers remains unresolved, with a trial date anticipated in Q4 2025 or Q1 2026. This creates uncertainty regarding the long-term exclusivity and revenue potential of the product.
Undiagnosed cancer-associated LEMS patients: The company estimates that 90% of cancer-associated LEMS patients remain undiagnosed, representing a significant challenge in expanding the addressable market for FIRDAPSE.
Royalty obligations for AGAMREE: The company faces increasing royalty obligations for AGAMREE as sales grow, including a $12.5 million milestone payment once net product revenue reaches $100 million. This could impact profitability.
R&D and operational costs: Increased R&D expenses, particularly for AGAMREE studies, and higher SG&A expenses due to the implementation of dedicated sales forces for FIRDAPSE and AGAMREE, could pressure margins.
2025 Revenue Guidance: Catalyst reaffirms its full-year 2025 revenue guidance of $545 million to $565 million, supported by strong performance across its product portfolio.
FIRDAPSE Revenue Guidance: The company reaffirms its full-year 2025 net product revenue guidance for FIRDAPSE at $355 million to $360 million, driven by durable demand and consistent execution.
AGAMREE Revenue Guidance: Catalyst reaffirms its full-year 2025 net product revenue guidance for AGAMREE at $100 million to $110 million, supported by strong patient retention and growing adoption.
FYCOMPA Revenue Guidance: The company reaffirms its full-year 2025 net product revenue guidance for FYCOMPA at $90 million to $95 million, despite anticipated revenue erosion from generic competition.
FIRDAPSE Growth Strategy: Catalyst is advancing a focused expansion strategy for FIRDAPSE, including HCP education, updated NCCN guidelines, and improved diagnostic access, aiming to expand its addressable market and sustain growth into 2026 and beyond.
AGAMREE Studies: The SUMMIT study for AGAMREE is progressing with 19 sites initiated and patient enrollment ongoing. Initial results from Phase I studies are expected by late 2025 to early 2026.
Patent Litigation for FIRDAPSE: Catalyst anticipates a trial date for ongoing patent litigation in Q4 2025 or Q1 2026, with a Markman hearing scheduled for October 7, 2025.
The selected topic was not discussed during the call.
The earnings call summary indicates strong financial performance and reaffirmed guidance, suggesting stability. However, the Q&A reveals uncertainties, such as the lack of specifics on FYCOMPA's brand loyalty and AGAMREE's life cycle management, which could temper investor enthusiasm. The oncology portion of FIRDAPSE is more of a long-term story, and the impact of generics on FYCOMPA remains unclear. The market cap indicates a moderate reaction is likely, leading to a neutral stock price movement prediction.
The earnings call summary highlights strong financial performance, with significant revenue and net income growth. Product development is promising, with market expansion for AGAMREE and strategic initiatives for FIRDAPSE. The Q&A reassures continued growth and strategic initiatives, though some uncertainty remains in R&D and SG&A. The market cap suggests a moderate reaction. Overall, the company's robust financial metrics, market strategy, and optimistic guidance outweigh minor uncertainties, indicating a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
